

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

UTILITY
PATENT APPLICATION
TRANSMITTAL(Only for new nonprovisional applications under
37 C.F.R. 1.53(b))

Attorney Docket No.

3211.1006-009

First Named Inventor or
Application Identifier

Keizo Koya

Express Mail Label No.

EL955641051US

Title of
Invention

2-Aroylimidazole Compounds for Treating Cancer

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

1. ☒ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification **Total Pages [76]**
(preferred arrangement set forth below)
- Descriptive title of the invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 113) **Total Sheets [1]**
☒ Fig. of the Drawings for Publication [1]
☐ No Figure to be Published
4. ☒ Oath or Declaration **Total Pages [3]**
- a. ☐ Newly executed (original or copy)
 - b. ☒ Copy from a prior application (37 C.F.R. 1.63(d))
(for continuation/divisional with Box 17 completed)
 - i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)

6. ☐ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
- a. ☐ Computer Readable Form
 - b. ☐ Paper Copy (identical to computer copy)
[] Pages
 - c. ☐ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. ☐ Assignment Papers (cover sheet & documents)
☒ Assignee - Synta Pharmaceuticals Corp.
Lexington, Massachusetts
8. ☐ Power of Attorney [] 37 C.F.R. 3.73(b) Statement
9. ☐ English Translation Document (if applicable)
10. ☒ Information Disclosure Statement (IDS)/PTO-1449 [X] Copies of IDS Citations
11. ☐ Preliminary Amendment
12. ☒ Return Receipt Postcard
13. ☐ Small Entity Statement(s)
- 14a. ☐ Foreign Priority Claim under 35 U.S.C. §119 or 365
- 14b. ☐ Certified Copy of Priority Document(s)
15. ☐ Nonpublication Request (check parent application)
16. ☒ Other Remarks Letter; and Copy of US 2003/0096836 A1 with Claims as Allowed 12/16/03 document.


17. If a CONTINUING APPLICATION, check appropriate box; supply the requisite information.

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 10/233,371

Prior application information: Examiner: D. M. Seaman Group Art Unit: 1625

The entire disclosure of the prior application is considered a part of the disclosure of the accompanying application and is hereby incorporated by reference.
(Add standard Related Applications section with incorporation by reference to specification or update same)

18. CORRESPONDENCE ADDRESS

NAME	Customer No. 021005				
	HAMILTON, BROOK, SMITH & REYNOLDS, P.C.				
ADDRESS	530 Virginia Road, P.O. Box 9133				
CITY	Concord	STATE	MA	ZIP CODE	01742-9133
COUNTRY	USA	TELEPHONE	(978) 341-0036	FAX	(978) 341-0136
Signature				Date	March 16, 2004
Submitted by Typed or Printed Name	Craig K. Anderson			Reg. Number	54,961

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

FEE TRANSMITTAL FOR PATENT APPLICATIONS	Attorney Docket Number	3211.1006-009
	Application Number	
	First Named Inventor	Keizo Koya

CLAIM CALCULATION (includes any preliminary amendment)

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(c) or (j))	33 - 20* =	13	x \$ 18 =	\$ 234
	INDEPENDENT CLAIMS (37 CFR 1.16(b) or (i))	5 - 3** =	2	x \$ 86 =	\$ 172
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))			+ \$ 290 =	\$
				BASIC FEE (37 CFR 1.16(a) or (h))	\$ 770
				Total of above Calculations =	\$ 1176
				Reduction by 50% for filing by small entity (37 CFR 1.9, 1.27, 1.28) =	\$
				TOTAL =	\$ 1176
				Surcharge - Late Filing of Declaration or Filing Fees (37 C.F.R. 1.16(e)) =	\$
				Petition for Extension of Time Fee (37 C.F.R. 1.17) =	\$
				Assignment Recordation Fee = (only when filed with application)	\$
				[Other]	\$
				TOTAL =	\$ 1176

* Reissue claims in excess of 20 and over original patent
 ** Reissue independent claims over original patent


1. Small entity status:

- a. ☐ A small entity statement is enclosed.
- b. ☐ A small entity statement was filed in the prior non-provisional application and such status is still proper and desired.
- c. ☐ Is no longer claimed.

2. ☒ A general authorization is hereby granted to charge deposit account number 08-0380 for any fees required under 37 CFR 1.16 and 1.17 in order to maintain pendency of this application. A copy of this authorization is enclosed for accounting purposes.

3. ☒ A check is enclosed for \$1,176. ☐ Please charge \$[] to Deposit Account No. 08-0380.

4. ☐ Other: _____

Signature		Date	March 16, 2004
Submitted by Typed or Printed Name	Kraig K. Anderson	Reg. Number	54,961

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Keizo Koya, Lijun Sun, Mitsunori Ono, David James, Weiwen Ying,
Shoujun Chen

Continuation Application of:

Application No.: 10/233,371
Filed: August 29, 2002
Title: 2-Aroylimidazole Compounds for Treating Cancer

Date: March 16, 2004

EXPRESS MAIL LABEL NO. EL955641051US

REMARKS

Mail Stop PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The above-captioned application is a continuation of application number 10/233,371 filed on August 29, 2002 to which priority is claimed under 35 U.S.C. §120.

The specification of the present application is substantially the same as that of the parent application. The related applications paragraph has been revised to include a specific reference to the parent application.

The specification has been revised to correct formatting and minor typographical errors, including amendments entered in the parent application. No new matter has been added.


Referring to locations in the parent application, these amendments include:

amending “-NR^aR^d” to “-N(R^aR^b)” to correct a typographical error at page 9, line 8;
deleted “are”, page 1, line 13;
deleted “a” at page 1, line 19;
“herinbelow” amended to “below” at page 10, line 15;
in the examples, reformatting the example titles;
in example 3, correcting name ending in “meth” to “methanone” page 18, line 26;
correcting the spelling of s”substituent”, various locations; and
in the abstract, amending “below” to “herein”, page 95, line 5.

All of the claims from the parent application have been omitted. A new claim set is being presented herein for examination claiming pharmaceutical compositions comprising compounds of the invention. The scope of the compounds in these claims is identical to the scope of the compounds described as included in pharmaceutical compositions in the parent application. Beyond adapting the claims to pharmaceutical compositions, the body of the claims have been amended to make minor typographical changes, e.g., amending “-NR^aR^d” to “-N(R^aR^b)” as above, and amending “or” in various claims to “and” to conform with proper Markush language. A newly executed declaration under 37 C.F.R. 1.63 is not believed to be necessary under 37 C.F.R. 1.63(d) or 1.67(b).

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 
Kraig K. Anderson
Registration No. 54,961
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: *March 16, 2004*